Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Castle BiosciencesCSTL +3.42%83 Revenue per Share is $12.03 as of Jun. 2026. GuruFocus rates CSTL with a GF Score™ of 83/100 and a GF Value™ of $29.83 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Castle Biosciences ranks better than 93.68% on this metric.
Castle Biosciences's revenue per share for the
three
months ended in Jun. 2026 was $3.41.
Castle Biosciences's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $12.03.
Warning Sign:
Castle Biosciences Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Castle Biosciences was 2.50% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 31.20% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 33.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Castle Biosciences's Revenue per Share or its related term are showing as below:
CSTL'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -4.2 Med: 32.1 Max: 44.7
Current: 31.2
During the past 9 years, Castle Biosciences's highest 3-Year average Revenue Per Share Growth Rate was 44.70% per year. The lowest was -4.20% per year. And the median was 32.10% per year.
CSTL's 3-Year Revenue Growth Rate is ranked better than 93.68% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.7
vs CSTL: 31.20
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Castle Biosciences Revenue per Share Related Terms
Castle Biosciences Revenue per Share Historical Data
* Premium members only.
The historical data trend for Castle Biosciences's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSTL vs OPK, FLGT, FRNM: Revenue per Share Comparison
For the Diagnostics & Research subindustry, Castle Biosciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Castle Biosciences PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where Castle Biosciences's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Castle Biosciences's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Castle Biosciences (CSTL) has a Revenue per Share of $12.03 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Castle Biosciences and its competitors. According to the industry distribution chart, Castle Biosciences ranks #12 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 6.3%.
Is Castle Biosciences' Revenue per Share too high?
Castle Biosciences' current Revenue per Share is $12.03. The Medical Diagnostics & Research industry median Revenue per Share is 1.70. Castle Biosciences' value of $12.03 is 607.6% above this industry median. Based on the distribution chart, Castle Biosciences ranks #12 out of 190 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Castle Biosciences has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Revenue per Share compare to OPK and FLGT?
According to the Medical Diagnostics & Research industry distribution chart, Castle Biosciences ranks #12 out of 190 companies for Revenue per Share. This places Castle Biosciences in the top 6% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 1.70. Castle Biosciences' value of $12.03 is 607.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Diagnostics & Research company?
The median Revenue per Share among Medical Diagnostics & Research companies is 1.70, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Castle Biosciences's current Revenue per Share of $12.03 is 607.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Castle Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median Revenue per Share is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Castle Biosciences's current Revenue per Share is $12.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.83, compared to a current price of $33.44 — trading 12.1% above its estimated fair value. The current Revenue per Share is $12.03 and 607.6% above the Medical Diagnostics & Research industry median of 1.70. Castle Biosciences' overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Revenue per Share is $12.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Castle Biosciences (CSTL) Overvalued in 2026?
Based on GuruFocus' analysis, Castle Biosciences stock appears to be overvalued.
The current stock price of $33.44 is trading 12.1% above its estimated GF Value™ of $29.83.
GuruFocus considers Castle Biosciences to be Modestly Overvalued.
Key valuation signals for CSTL:
Revenue per Share: $12.03
GF Value™: $29.83 vs. price of $33.44 (12.1% above fair value)
Industry Position: 607.6% above the Medical Diagnostics & Research median (#12 of 190)
No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
83GF Score
Get the complete analysis for CSTL
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSTL has been successfully added to your 
